Vaping inflames the brain

Innovation
Jul.05.2022
Perhaps it is not the healthier option we perceive it to be...

Rates of eCigarette and vaping product consumption have risen dramatically in recent years. In the UK over just the 5 year period from 2012 to 2017 it climbed by several hundred percent. Many users are former smokers who regard vaping as a healthier option and have switched for that reason. But there’s also a - for the moment small but - growing cohort of “never smokers” who vape because it’s perceived to be low risk. Could it be though that, in the same way that it took decades of following up smoking doctors before Richard Doll could categorically say that smoking causes health harms, vaping - being a relatively new phenomenon - just doesn’t have the data yet for us to know what the health risks are? This is very much the view of UCSD’s Laura Crotty-Alexander…

 

Laura - In terms of whether the e-cigarette aerosol mixture is safer than conventional tobacco smoke, it looks like it is going to have fewer health effects, but it will have its own set of health effects.

 

Chris - Which could be different and remote and, in fact, manifest in a different part of the body, presumably, if they're different chemicals then what's in cigarettes.

 

Laura - Absolutely. Cigarette smoke contains about 7,000 chemicals and that use of cigarettes leads to damage across the body. Everywhere from your lips, where it first makes contact, all the way down to the GI tract and out to the skin and to the brain. And what we sought to find was whether e-cigarette aerosols could also impact all these different organs across the body.

 

Chris - How did you do it?

 

Laura - We used a mouse model. So we have this special setup where we take the mice and we put them in a little pie-shaped wedge container where they can move around. And then we use e-cigarettes that we have bought on regular websites and we give them a puff of e-cigarette aerosol and then regular air. And we have them breathe that in for 30 minutes, three times a day.

 

Chris - And is the mouse dose equivalent to what a human consuming these products would get? Or are the mice getting a much bigger impact and a bigger dose? Because obviously a human breath would be massive for a mouse.

 

Laura - We do try our best to design these mouse models to mimic human use, which is why we expose the mice multiple times a day, because a lot of humans use e-cigarettes throughout the day. And when we take one puff that's more human sized, we actually put it into a large chamber where it diffuses. So 16 mice are breathing in that aerosol.

 

Chris - And how do you then marry up what that intake is doing in different parts of the body?

 

Laura - We actually harvest the mice and then we take all the different body parts. And we look at them using special tools that look at gene expression or levels of protein. And we actually even look at organ function. And so we use these different measures to try and determine whether inhaling these e-cigarette aerosols over months leads to changes in these organs.

 

Chris - And what crops up when you do this? Do you see systemic effects?

 

Laura - Yes. So I was very surprised that we found profound changes in the brain in particular of these mice that inhaled Juul mint and Juul mango, which are two flavors that were very popular at the time we started this study. And both of those aerosols led to inflammation in the brain, which is shocking because the brain is a protected compartment. So it was very worrisome that inhaling the e-cigarette aerosols for just a month led to very impressive levels of inflammation in a part of the brain that controls mood and behaviour and memory.

 

Chris - Are you saying that it's specifically the flavours that are doing that? So this is an effect beyond the addictive qualities of the nicotine and so on?

 

Laura - In the brain, the fact that we saw similar changes in both flavours indicated more that it was the nicotine and the other substances at the core of these e-liquids that were driving the changes. But, for example, in the heart, we found that the mint flavour really changed and drove inflammation, whereas the mango flavour did not. And so that comparison helped us to understand that maybe the heart effects are maybe particularly driven by the mint flavour and not the nicotine in other components.

 

Chris - We'll come on in a second to what the impact of that might be, but just considering for a minute the fact you've got this effect - how does it compare in scale with if the mice were just (if mice could) smoking normal cigarettes?

 

Laura - If I were to look back at the historic data, I would say that the neurologic effects are of a scale that appears to be either equal to, or greater than what is seen in conventional tobacco. And that the effects are different.

 

Chris - We believe that chronic inflammation might be linked to at least the progression, if not in some cases the cause, of certain neurodegenerative conditions and probably also degeneration in other organs. So do you think then that this is indicative of the fact that people doing this could be speeding up the aging process of their brain? They're effectively bringing forward the age at which they may well succumb to degenerative conditions of the nervous system?

 

Laura - I absolutely agree that that is a concern. And in addition, the changes in these parts of the brain suggest that people who are using e-cigarettes may have more anxiety and depression and might have sort of permanent changes to their behaviour patterns.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Product | PMI Launches TEREA Black Mint Pearl in Japan, Adding First Capsule Variant to Black Range With Nationwide Rollout From October 19
Product | PMI Launches TEREA Black Mint Pearl in Japan, Adding First Capsule Variant to Black Range With Nationwide Rollout From October 19
Philip Morris Japan (PMJ) launched TEREA Black Mint Pearl on October 15, 2026, introducing the first capsule-equipped heated tobacco stick in the TEREA Black range for IQOS ILUMA devices. The product combines a strong menthol profile with a crushable mint capsule and is priced at ¥640 per 20-stick pack, including tax. Sales began at four IQOS stores and selected retail partners on October 15, with distribution expanding to convenience stores and other tobacco retailers nationwide from October 19. The launch brings Japan's TEREA portfolio to 28 variants, including 21 menthol-related products, or 75% of the range.
product
Oct.16 by 2Firsts Perspectives
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
At the 2026 NACS Show, Altria displayed Ploom devices alongside imagery of Marlboro-branded heated tobacco sticks, while also featuring RIOT Energy and Proper Wild non-nicotine products. The booth showcased on! PLUS nicotine pouches, including 12 mg variants not listed among FDA-authorized products as of October 9, and NJOY e-cigarettes. Altria also presented convenience-store traffic figures highlighting its retail presence. 2Firsts examines the company's expanded product portfolio, non-nicotine business activities and the regulatory status of products displayed at the show.
EXPO
Oct.10
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
China exported $979 million of vape-related products in August 2026, up 3.3% from a year earlier but down 6.4% from July. The UK replaced the U.S. as the main source of growth: UK-bound shipments jumped 51.4% to a 2026 high of $177 million, while exports to the U.S. fell 12.4% to $339 million. Shipments to markets outside the U.S. increased 14.2%, broadening growth beyond the market that had driven July’s rebound.
News
Sep.23 by 2Firsts Perspectives
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27